BACKGROUND & AIMS: The endocannabinoid and eicosanoid lipid signaling pathways have important roles in inflammatory syndromes. Monoacylglycerol lipase (MAGL) links these pathways, hydrolyzing the endocannabinoid 2-arachidonoylglycerol to generate the arachidonic acid precursor pool for prostaglandin production. We investigated whether blocking MAGL protects against inflammation and damage from hepatic ischemia/reperfusion (I/R) and other insults. METHODS: We analyzed the effects of hepatic I/R in mice given the selective MAGL inhibitor JZL184, in Mgll(-/-) mice, fatty acid amide hydrolase(-/-) mice, and in cannabinoid receptor type 1(-/-) (CB1-/-) and cannabinoid receptor type 2(-/-) (CB2-/-). Liver tissues were collected and analyzed, along with cultured hepatocytes and Kupffer cells. We measured endocannabinoids, eicosanoids, and markers of inflammation, oxidative stress, and cell death using molecular biology, biochemistry, and mass spectrometry analyses. RESULTS: Wild-type mice given JZL184 and Mgll(-/-) mice were protected from hepatic I/R injury by a mechanism that involved increased endocannabinoid signaling via CB2 and reduced production of eicosanoids in the liver. JZL184 suppressed the inflammation and oxidative stress that mediate hepatic I/R injury. Hepatocytes were the major source of hepatic MAGL activity and endocannabinoid and eicosanoid production. JZL184 also protected from induction of liver injury by D-(+)-galactosamine and lipopolysaccharides or CCl4. CONCLUSIONS: MAGL modulates hepatic injury via endocannabinoid and eicosanoid signaling; blockade of this pathway protects mice from liver injury. MAGL inhibitors might be developed to treat conditions that expose the liver to oxidative stress and inflammatory damage.
BACKGROUND & AIMS: The endocannabinoid and eicosanoidlipid signaling pathways have important roles in inflammatory syndromes. Monoacylglycerol lipase (MAGL) links these pathways, hydrolyzing the endocannabinoid2-arachidonoylglycerol to generate the arachidonic acid precursor pool for prostaglandin production. We investigated whether blocking MAGL protects against inflammation and damage from hepatic ischemia/reperfusion (I/R) and other insults. METHODS: We analyzed the effects of hepatic I/R in mice given the selective MAGL inhibitor JZL184, in Mgll(-/-) mice, fatty acid amide hydrolase(-/-) mice, and in cannabinoid receptor type 1(-/-) (CB1-/-) and cannabinoid receptor type 2(-/-) (CB2-/-). Liver tissues were collected and analyzed, along with cultured hepatocytes and Kupffer cells. We measured endocannabinoids, eicosanoids, and markers of inflammation, oxidative stress, and cell death using molecular biology, biochemistry, and mass spectrometry analyses. RESULTS: Wild-type mice given JZL184 and Mgll(-/-) mice were protected from hepatic I/R injury by a mechanism that involved increased endocannabinoid signaling via CB2 and reduced production of eicosanoids in the liver. JZL184 suppressed the inflammation and oxidative stress that mediate hepatic I/R injury. Hepatocytes were the major source of hepatic MAGL activity and endocannabinoid and eicosanoid production. JZL184 also protected from induction of liver injury by D-(+)-galactosamine and lipopolysaccharides or CCl4. CONCLUSIONS:MAGL modulates hepatic injury via endocannabinoid and eicosanoid signaling; blockade of this pathway protects mice from liver injury. MAGL inhibitors might be developed to treat conditions that expose the liver to oxidative stress and inflammatory damage.
Authors: Sándor Bátkai; Douglas Osei-Hyiaman; Hao Pan; Osama El-Assal; Mohanraj Rajesh; Partha Mukhopadhyay; Feng Hong; Judith Harvey-White; Anjum Jafri; György Haskó; John W Huffman; Bin Gao; George Kunos; Pál Pacher Journal: FASEB J Date: 2007-02-27 Impact factor: 5.191
Authors: Sándor Bátkai; Partha Mukhopadhyay; Bėla Horváth; Mohanraj Rajesh; Rachel Y Gao; Anu Mahadevan; Mukkanti Amere; Natalia Battista; Aron H Lichtman; Lisa A Gauson; Mauro Maccarrone; Roger G Pertwee; Pál Pacher Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: B Brocato; A A Zoerner; Z Janjetovic; C Skobowiat; S Gupta; B M Moore; A Slominski; J Zhang; M Schenone; R Phinehas; R J Ferry; E Dick; G B Hubbard; G Mari; N Schlabritz-Loutsevitch Journal: Placenta Date: 2013-09-02 Impact factor: 3.481
Authors: Patricia Rivera; Antonio Vargas; Antoni Pastor; Anna Boronat; Antonio Jesús López-Gambero; Laura Sánchez-Marín; Dina Medina-Vera; Antonia Serrano; Francisco Javier Pavón; Rafael de la Torre; Ekaitz Agirregoitia; María Isabel Lucena; Fernando Rodríguez de Fonseca; Juan Decara; Juan Suárez Journal: Br J Pharmacol Date: 2020-04-15 Impact factor: 8.739
Authors: John D Douglass; Yin Xiu Zhou; Amy Wu; John A Zadroga; Angela M Gajda; Atreju I Lackey; Wensheng Lang; Kristen M Chevalier; Steven W Sutton; Sui-Po Zhang; Christopher M Flores; Margery A Connelly; Judith Storch Journal: J Lipid Res Date: 2015-04-04 Impact factor: 5.922